Skip to main content

Table 2 Trial Data: Number of patients N; improvement in HAQ score Δ HAQ; number of ACR20, ACR50, ACR70 responders; HAQ score at baseline HAQ base ; + indicates additional treatment with MTX

From: The use of continuous data versus binary data in MTC models: A case study in rheumatoid arthritis

Trial

Arm

N

ΔHAQ(SD)

ACR20

ACR50

ACR70

HA Q base

Weinblatt et al. [31]

P+

62

0.27 (0.6)

9

5

3

1.64

 

Ada+

69

0.54 (0.6)

33

22

7

1.52

 

Ada+

67

0.62 (0.6)

45

37

18

1.55

 

Ada+

73

0.59 (0.5)

48

31

14

1.55

Keystone et al. [32]

P+

200

0.24 (0.5)

59

19

5

1.45

 

Ada+

207

0.56 (0.5)

131

81

43

1.44

 

Ada+

212

0.60 (0.5)

129

87

37

1.48

Van de Putte et al. [33]

P

110

0.07 (0.5)

21

9

2

1.88

 

Ada

112

0.39 (0.6)

44

23

11

1.88

 

Ada

106

0.29 (0.6)

38

20

9

1.88

 

Ada

103

0.49 (0.5)

55

36

19

1.84

 

Ada

113

0.38 (0.6)

52

25

14

1.83

Miyasaka [34]

P

87

-0.1 (0.6)

12

5

1

1.39

 

Ada

87

0.2 (0.5)

25

14

9

1.57

 

Ada

91

0.2 (0.6)

40

22

11

1.64

 

Ada

87

0.4 (0.6)

44

28

13

1.77

Kim at el. [35]

P+

63

0.2 (0.5)

23

9

5

1.3

 

Ada+

65

0.5 (0.6)

40

28

14

1.4

Maini et al. [36]

P+

88

0.3 (0.5)†

18

7

0

1.8

 

Inf+

86

0.3 (0.5)†

45

22

7

1.8

 

Inf+

86

0.5 (0.5)†

47

25

9

1.8

 

Inf+

87

0.5 (0.6)†

51

26

15

1.8

 

Inf+

81

0.4 (0.5)†

49

21

9

1.5

Westhoven et al.[37]

P+

363

-

87

33

16

1.5

 

Inf+

360

-

199

110

48

1.5

 

Inf+

361

-

205

119

54

1.5

Zhang et al. [38]

P+

86

0.45 (-)

42

22

12

1.6

 

Inf+

87

0.76 (-)

66

38

20

1.6

Schiff et al. [39]

P+

110

-

49

22

10

1.8

 

Inf+

165

-

98

61

40

1.7

Moreland et al. [40]

P

80

0.03 (-)

9

4

1

1.7

 

Eta

76

0.58 (-)

39

18

7

1.7

 

Eta

78

0.62 (-)

46

31

12

1.6

Weinblatt et al. [41]

P+

30

0.4 (-)

8

1

0

1.5

 

Eta+

59

0.7 (-)

42

23

9

1.5

Keystone et al. [42]

P+

133

0.13red* (0.4)‡

37

18

7

1.25*

 

Gol

133

0.13* (0.7)‡

47

26

15

1.38*

 

Gol+

89

0.38* (0.5)‡

53

33

18

1.38*

 

Gol+

89

0.5* (0.5)‡

53

29

16

1.38*

Kay et al. [43]

P+

35

-

13

2

0

1.3

 

Gol+

35

-

21

13

3

1.7

 

Gol+

34

-

19

10

6

1.8

Keystone et al. [44]

P+

199

0.18 (-)

27

15

6

1.7

 

Cert+

393

0.60 (-)

231

146

84

1.7

 

Cert+

390

0.63 (-)

237

156

79

1.7

Smolen et al. [45]

P+

127

0.14 (0.5)

11

4

1

1.6

 

Cert+

246

0.5 (0.5)

141

80

39

1.6

 

Cert+

246

0.5 (0.5)

142

81

26

1.6

Fleischmann et al. [46]

P

109

-0.07 (0.4)†

10

4

0

1.6

 

Cert

111

0.39 (0.7)†

51

25

9

1.4

  1. Ada=adalimumab; Inf=infliximab; Eta=etanercept; Gol=golimumab, Cert=certolizumab, P=placebo. *Median; ‡estimated from IQR; †data provided by authors following request.